# PANKU-Breast02: HCP commentary report

> 125 verified statements (34 from clinicians verified by NPI or staff page) from 28 commentary sources · 7 findings · updated Nov 1, 2026

## Report

- Trial: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
- NCT ID: NCT06382142
- Registry: https://clinicaltrials.gov/study/NCT06382142
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: izalontamab brengitecan (BL-B01D1)
- Indication: unresectable locally advanced or metastatic triple-negative breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: d66ded642427f6853062e4a9fda64eddeb0de2d616ff84cf3f9497addf5b3ca3

## Counts

- HCP commentary sources screened: 50
- Sources cited by verified statements: 28
- Verified statements: 125
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 34
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Voices cited: 15
- Cited voices identity-verified: 12
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PANKU-Breast02 compares BL-B01D1 with chemotherapy after taxane failure in unresectable locally advanced or metastatic triple-negative breast cancer; the benefit–risk discussion centers on toxicity and supportive care. The report cites seven physicians, six of them medical oncologists. Beyond applicability outside China, the open question is what evidence, supportive care and access would justify BL-B01D1 after a prior topoisomerase I antibody–drug conjugate. The sources reviewed for this edition place PANKU-Breast02 results at ASCO 2026.

## Open Medical Affairs question

For patients reaching this post-taxane decision after a prior ADC, what evidence would justify choosing iza-bren, and under what supportive-care and access conditions?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Substantial toxicity makes supportive care central to the benefit–risk discussion
- F2. Activity after a prior topoisomerase I ADC remains an unanswered treatment-sequencing question
- F3. Strong efficacy enthusiasm coexists with an explicitly incremental view of survival progress
- F4. One favorable assessment specifically challenges the heterogeneous chemotherapy control
- F5. China-only evidence prompts development optimism and a call for broader applicability
- F6. Bispecific targeting is attractive because of heterogeneity, but its proposed advantages remain hypotheses
- F7. A possible future option is not the same as an established standard or an available treatment

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 12 | 9 | 6 | 6 | recorded | 3 |
| F2 | 8 | 6 | 4 | 4 | recorded | 3 |
| F3 | 10 | 11 | 6 | 6 | recorded | 3 |
| F4 | 1 | 1 | 1 | 1 | recorded | 3 |
| F5 | 8 | 9 | 5 | 5 | recorded | 3 |
| F6 | 10 | 12 | 5 | 5 | recorded | 3 |
| F7 | 11 | 8 | 6 | 4 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 1 | 0 | 0 | 4 | 12 | 1 | 4 posts and articles, 2 podcasts and video | yes |
| F2 | 4 | 4 | 0 | 0 | 0 | 8 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F3 | 10 | 0 | 0 | 0 | 0 | 12 | 3 | 5 posts and articles, 1 podcast or video | yes |
| F4 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 post or article | yes |
| F5 | 6 | 1 | 0 | 0 | 1 | 9 | 1 | 3 posts and articles, 2 podcasts and video | yes |
| F6 | 7 | 2 | 0 | 0 | 1 | 11 | 3 | 2 posts and articles, 3 podcasts and video | yes |
| F7 | 6 | 3 | 0 | 0 | 2 | 12 | 0 | 1 post or article, 5 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS): F1 (1 shared claims), F3 (4 shared claims), F7 (1 shared claims)
- Primary endpoint: Overall survival (OS): F1 (1 shared claims), F2 (1 shared claims), F3 (6 shared claims), F7 (1 shared claims)
- Secondary endpoints: F1 (5 shared claims), F3 (1 shared claims), F5 (1 shared claims), F7 (2 shared claims)
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F5 (1 shared claims), F6 (1 shared claims), F7 (4 shared claims)
- The comparison: F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F7 (2 shared claims)
- Safety and tolerability: F1 (11 shared claims), F5 (1 shared claims), F7 (4 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F3 (1 shared claims), F5 (2 shared claims), F6 (1 shared claims), F7 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F7. A possible future option is not the same as an established standard or an available treatment

An X-thread post asks which antibody–drug conjugate should follow taxane-containing therapy in metastatic triple-negative breast cancer, and for which patients.

Source: X thread, 2026-06-11.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 125 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 28 | Counts free |
| Speaker attribution for cited voices | 15 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) | discussed | 23 | 19 |
| Primary endpoint: Overall survival (OS) | discussed | 26 | 19 |
| Secondary endpoints | discussed | 8 | 5 |
| Population and setting | discussed | 15 | 11 |
| The comparison | discussed | 13 | 12 |
| Safety and tolerability | discussed | 19 | 10 |
| Design and conduct | discussed | 13 | 9 |
| ADC sequencing and resistance at the post-taxane decision | discussed | 11 | 6 |
| Geographic applicability, international development, regulation and access | discussed | 16 | 9 |
| Bispecific design, target selection and proposed biological advantages | discussed | 25 | 10 |
| Clinical significance, prospective treatment role and communication of enthusiasm | discussed | 28 | 18 |
| AI forecasts and retrospective model-performance commentary | discussed | 3 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 35 | 18 |
| YouTube | 8 | 7 |
| Bluesky threads | 4 | 0 |
| Podcasts | 2 | 2 |
| LinkedIn posts | 1 | 1 |

- Screened window: 2026-02-26 to 2026-10-20
- Cited window: 2026-02-26 to 2026-09-03
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure
- Registry: NCT06382142 (https://clinicaltrials.gov/study/NCT06382142)
- Study IDs: BL-B01D1-307
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 418 (actual)
- Start: 2024-06-21 (actual)
- Primary completion: 2026-01-13 (actual)
- Primary endpoint: Progression-free survival (PFS) (Up to approximately 24 months)
- Primary endpoint: Overall survival (OS) (Up to approximately 24 months)
- Intervention: BL-B01D1 (drug)
- Intervention: Eribulin (drug)
- Intervention: Vinorelbine (drug)
- Intervention: Gemcitabine (drug)
- Intervention: Capecitabine (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on standard-of-care adoption in pretreated metastatic triple-negative breast cancer.
- Not yet captured in this edition: a view on treatment choice and tolerability in previously treated advanced triple-negative breast cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Multiple posts, clips and formats can repeat the same discussion rather than provide independent agreement.
- Some potentially relevant passages were not fully assessed, and discussion that does not use familiar study names or identifiers may be absent. Additional qualifications or dissent may therefore be missing.
- No protocol or original full trial-results publication was available. Numerical efficacy and safety findings are reported as what the contributors said, not as an independent analysis of the complete dataset.
- Several passages cannot be assigned to a named speaker. Clinical roles are not established for every named contributor; source-stated credentials and trial involvement remain descriptions made by those sources.
- Organizations, AI-generated forecasts, relayed presentation summaries and reposts must not be counted as additional independent HCP opinions.
- Early topline and abstract-based comments reflect the information available in those particular communications. Differences in detail or publication date do not by themselves establish a change of mind.
- Reported enrollment figures are inconsistent across posts and, in one post, with the separately listed arm sizes. These figures are not reconciled.
- Regulatory information is incomplete. Expected FDA evidence requirements and descriptions of pending access are not formal regulatory decisions or proof of current availability in every location.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (125 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (12 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/panku-breast02-nct06382142
- Agents: POST https://www.erudio.com/api/orders with {"report": "panku-breast02-nct06382142", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=panku-breast02-06382142

## Cite

Erudio Health. PANKU-Breast02 (NCT06382142): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/panku-breast02-nct06382142

## Machine access

- JSON: https://www.erudio.com/reports/panku-breast02-nct06382142.json
- Markdown: https://www.erudio.com/reports/panku-breast02-nct06382142.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "panku-breast02-06382142"}`